Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

Slides:



Advertisements
Similar presentations
Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Non-valvular Atrial Fibrillation.
Advertisements

Addressing the Challenges in Primary and Secondary Stroke Prevention
Covering the Bases in Cardioversion
Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors.
Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.
Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.
Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.
NOACs In Long-term VTE Treatment: A State Of The Art Review
Updates in Anticoagulation: What Did We Learn From ESC 2017?
US Guidelines US Guidelines Low-risk Patients.
When Is Adding Aspirin to NOACs Worth the Risk?
Barriers to Oral Anticoagulant Use for Stroke Prevention in AF
Thrombosis, Cancer, and NOACs
Access to NOAC Therapy:
NOACs in Clinical Practice: Are They All the Same?
Appropriate Stroke Prevention Strategies in Atrial Fibrillation
A New Era for NOACs:.
POWER IN NUMBERS: REVISITING EFFICACY & SAFETY OF NOACS IN AF
Anticoagulation Highlights From the American Heart Association Meeting 2017.
Up to Date on Which NOAC for Which Patient
Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.
REVERSAL AGENTS FOR NOACS: Do WE NEED THEM in THE EP LAB?
Oral Anticoagulants in AFa,b A Brief History.
Surveying the Safety of NOACs in the Real World
Selecting NOACs for High-Risk Patients
Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI
NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS
How to Adjust Anticoagulant Dosing
Revealing Characteristics of Patients at High Risk for Developing Atrial Fibrillation.
The Essentials for Secondary Stroke Prevention
Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:
Seizures in the Elderly: Treatment and Special Considerations
Efficacy and Safety of Edoxaban in Patients With AF and HF
Access to NOAC Therapy:
Adherence in SPAF: Measures to Improve Care
What Anticoagulant Registries Are Revealing
A Better Solution For Cancer Patients With VTE?
VTE in Cancer.
Reversal Strategies for VKA: Truths and Misconceptions
Oral Anticoagulation in AF
Real-World Evidence in VTE
Dos and Don’ts for High-Risk Elderly Patients With AF
Practical Considerations to Extend Treatment for VTE
Atrial Fibrillation.
Extraordinary Cases of VTE Prevention in Patients With Cancer
Taking the "Cryptogenic" Out of Cryptogenic Stroke
NOACs in AF: Consequences of Underdosing and NonAdherence
Identifying High-Risk AF Patients
Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?
What You Didn't Know About AF and Renal Dysfunction
Cancer-Associated Thrombosis
Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?
Updates in Anticoagulation: Key Sessions at ESC 2017
NOAC Studies in VTE AF Studies Superior Outcomes.
NOACs in AF: Consequences of Underdosing and NonAdherence
An Unmet Need.
Disease Burden of VTE Phases of VTE Treatment.
Taking the "Cryptogenic" Out of Cryptogenic Stroke
5 Good Minutes on Atrial Fibrillation-related Stroke
Björn Redfors et al. JACEP 2017;j.jacep
VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.
How to Adjust Anticoagulant Dosing
Antiarrhythmic Drugs in AF
Uptitration of Medications in HF: Start Low but Aim High and Stay High
Real-World Data in Cardiology: Focus on Atrial Fibrillation
Top Tips in Evidence-Based Care for HFrEF
Extraordinary Cases in Stroke Prevention
Antithrombotic Therapy in AF Patients Undergoing PCI
Treating Pulmonary Embolism Today
Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?
Presentation transcript:

2016 ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More

Introduction

Principles of AF Management

2016 ESC Guidelines for Diagnosis and Management of AF: Key Recommendations

2016 ESC Guidelines for Diagnosis and Management of AF: Key Recommendations (cont)

2016 ESC Guidelines for Diagnosis and Management of AF: Key Recommendations (cont)

2016 ESC Guidelines for Diagnosis and Management of AF: Key Recommendations (cont)

Real-World Data: An Important Source of Evidence

Real-World Data: NOACs

Drug Adherence and Persistence Results

Real-World Data: NOACS (cont)

Risk of Bleeding Among Elderly Patients on NOACs

Real-World Data: NOACs (cont)

Persistence of NOACs by Cohort Among NOAC-Naive Patients

Real-World Data: NOACs (cont)

Propensity Score-Matched Adjusted Incidence Rates of Major Bleeding Propensity Score-Matched Adjusted Incidence Rates of Major Bleeding* and HRs for Anticoagulant Initiation

Real-World Data: NOACs (cont)

Real-World Data: NOACs (cont)

ENSURE-AF: Edoxaban for Cardioversion of AF

Ensure-AF: Primary Efficacy Endpoint Results

Stroke Prevention in AF: Some Important Considerations

Things to Consider When Starting/Choosing a NOAC . . . Think ABCDE

Summary and Conclusions

Abbreviations

Abbreviations